UBS O'Connor’s Revolution Medicines RVMD Stock Holding History

UBS O'Connor’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-30,000	Closed	-$657K	–	431
2020 Q1	$657K	Buy	+30,000	New	+$830K	0.01%	248

Other funds holding RVMD

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS O'Connor's RVMD Position: Q2 2020 in Review

UBS O'Connor sold out of Revolution Medicines (RVMD) in Q2 2020, closing a stake of 30,000 shares — an estimated $657K sold.

UBS O'Connor first reported a position in RVMD in Q1 2020 and held it in 1 quarter. The position peaked at $657K in Q1 2020. 77 funds tracked by Wall St. Rank hold RVMD as of Q2 2020.

UBS O'Connor reported no remaining Revolution Medicines position as of Q2 2020 after selling out during the quarter.
UBS O'Connor sold 30,000 Revolution Medicines shares in Q2 2020, an estimated $657K.
UBS O'Connor first reported a position in Revolution Medicines in Q1 2020 and held it in 1 quarter.
UBS O'Connor's Revolution Medicines position peaked at $657K in Q1 2020.
77 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2020.

Based on UBS O'Connor's 13F filing for Q2 2020, filed 13 Aug 2020.